Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Pacira BioSciences, Inc. (PCRX) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $925.6M. Revenue grew 3.6% year-over-year and the company generated $136.7M in free cash flow. This page tracks PCRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 788 employees · IPO Feb 3, 2011
Valuation
Valuation & price
$22.64 · as of May 17, 2026 · -16.8% vs 52w high
145.0
P/E ratio
Latest-FY diluted EPS
1.34
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$925.6M
Market cap
3.6%
Revenue growth (YoY)
79.4%
Gross margin
$136.7M
Free cash flow (USD)
$216M
Net debt
-3.6%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 30, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventDivestiture AnnouncementJun 30, 2026Filing
- Insider sellInsider Sell $144K · 10b5-1 PlanRIKER LAUREN · Senior Vice President, Finance · $143.7KJun 12, 2026Filing
- 8-K eventEmployee Stock Purchase Plan AmendedJun 11, 2026Filing
- Insider sellInsider Sell $228K · 10b5-1 PlanWILLIAMS KRISTEN · Chief Administrative Officer · $228.5KJun 5, 2026Filing
- 8-K eventEarnings ReleaseApr 30, 2026Filing
- Quarterly report10-Q FiledApr 30, 2026Filing
- Insider sellInsider Sell $326K · 10b5-1 PlanCross Shawn · Chief Financial Officer · $325.6KApr 24, 2026Filing
- Insider sellInsider Sell $303K · 10b5-1 PlanCross Shawn · Chief Financial Officer · $302.6KApr 22, 2026Filing
Questions
Frequently asked questions
What is Pacira BioSciences, Inc.'s market cap?
Pacira BioSciences, Inc. (PCRX) has a market capitalization of $925.6M.
What is PCRX's P/E ratio?
PCRX trades at a price-to-earnings ratio of 145.0, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is PCRX's price-to-book (P/B) ratio?
PCRX trades at 1.34 times book value per share.
Are insiders buying PCRX stock?
SEC Form 4 filings show no open-market insider buys at Pacira BioSciences, Inc. in the last 90 days (4 sells).
Same arena
Related companies in Drug Manufacturers - Specialty & Generic
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.